• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Regeneron Pharmaceuticals (NQ: REGN )

    838.20 -84.59 (-9.17%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Regeneron Pharmaceuticals

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    41 42 Next >
    Regeneron Pharmaceuticals' Approach To Improve Quality Of Weight Loss Has Merit: Goldman Sachs
    Regeneron Pharmaceuticals released data from a Phase 1 study on garetosmab and trevogrumab at the ADA meeting, showing significant increases in lean mass and reductions in fat mass in healthy... 
    Via Benzinga
    The Analyst Verdict: Regeneron Pharmaceuticals In The Eyes Of 13 Experts
    Via Benzinga
    5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
    Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach. 
    Via Benzinga
    Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
    Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments. 
    Via Benzinga
    $100 Invested In This Stock 20 Years Ago Would Be Worth $10,000 Today
    Via Benzinga
    Peering Into Regeneron Pharmaceuticals's Recent Short Interest
    Via Benzinga
    Competitor Analysis: Evaluating Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
    Via Benzinga
    Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for June 2024
    Investors looking for companies with high growth potential should consider investing in these three strong buy Cathie Wood stocks. 
    Via InvestorPlace
    Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Regeneron's Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market
    Analyst projects Regeneron's Dupixent to drive COPD sales surge, envisioning $20B market by 2026 on larger addressable market. 
    Via Benzinga
    Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
    The companies are closing in on the finish line for two new COPD treatments. 
    Via Investor's Business Daily
    Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club
    Enthusiasm is growing for a looming approval in COPD treatment. 
    Via Investor's Business Daily
    Navigating 14 Analyst Ratings For Regeneron Pharmaceuticals
    Via Benzinga
    2 Biotech Stocks to Buy in May
    You could buy these in any month, really. 
    Via The Motley Fool
    (REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
    Via Benzinga
    Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
    Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform. 
    Via Benzinga
    Stock Split Watch: 3 Growth Stocks That Could Be Next
    Success has some downsides, including a much higher stock price. 
    Via The Motley Fool
    What's Going On With FibroGen Stock Tuesday?
    FibroGen Inc (NASDAQ:FGEN) shares are trading higher Tuesday morning after the company said the FDA cleared its Investigational New Drug (IND) of FG-3165. FibroGen also announced a new clinical trial... 
    Via Benzinga
    Exposures Product Safety
    FibroGen Stock Is Surging After The Bell: What's Going On?
    FibroGen shares are moving higher in Monday's after-hours session after the company announced the FDA cleared its Investigational New Drug (IND) FG-3165. The company also announced a new clinical trial... 
    Via Benzinga
    Exposures Product Safety
    Here's How Much $100 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth Today
    Via Benzinga
    FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease
    The FDA extends the target action date for reviewing Dupixent as an add-on treatment for uncontrolled COPD to September 27, 2024. This follows the submission of additional efficacy analyses from... 
    Via Benzinga
    Exposures Product Safety
    Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    What's Going On With Biohaven Stock Wednesday?
    The company announced it dosed a patient with a new possible treatment for certain cancers, showcased positive data from two different studies and presented other updates. 
    Via Benzinga
    After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February
    Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnoses, and medications. 
    Via Benzinga
    Topics Data Breach
    Exposures Information Security
    Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    3 Stocks That Have Turned $25,000 Into More Than $1 Million in 15 Years
    It might not be too late to invest in these impressive growth stocks. 
    Via The Motley Fool
    Large Cap Biopharmaceuticals Performance
    The biotech sector remains a laggard YTD as can be seen by the IBB​​​​​​​. 
    Via Talk Markets
    Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    41 42 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.